Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.39 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LOX | P28300 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3186703 | 0.79 | SMN1; SMN2 (0.38) | GAARECQLKDM4ETHRBL3MBTL1 | |
| SCHEMBL21325014 | 0.77 | KDM4E (0.36) | GAARECQLKDM4ETHRBL3MBTL1 | |
| SCHEMBL19398113 | 0.73 | AXL (0.34) | GAARECQLAXLALDH1A1MAPT | |
| SCHEMBL89524 | 0.67 | — | — | |
| SCHEMBL11217688 | 0.64 | — | — | |
| SCHEMBL1659954 | 0.62 | — | — | |
| SCHEMBL8911551 | 0.62 | — | — | |
| SCHEMBL16554341 | 0.62 | — | — | |
| SCHEMBL20095237 | 0.62 | — | — | |
| SCHEMBL1067276 | 0.60 | SMN1; SMN2 (0.38) | KDM4EL3MBTL1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210186958-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-06-24 | — | — | US | disclosed |
| US-10005740-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180118696-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-03 | — | — | US | disclosed |
| US-9783507-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170144971-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170137388-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-05-18 | — | — | US | disclosed |
| US-9637493-B2 | Substituted pyrrolopyrimidines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9603819-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| US-9593110-B2 | Neprilysin inhibitors | Theravence Biopharma R&D IP, LLC (US) | 2017-03-14 | — | — | US | disclosed |
| US-9540377-B2 | 2,6,7,8 substituted purines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| EP-2253315-A1 | Alkoxyphenylpropanoic acid derivatives | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
| US-7517910-B2 | Alkoxyphenylpropanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20070213364-A1 | Alkoxyphenylpropanoic Acid Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-09-13 | — | — | US | disclosed |
| EP-1731505-A1 | ALKOXYPHENYLPROPANOIC ACID DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2006-12-13 | — | — | EP | disclosed |
| EP-0673246-A1 | USE OF ALKYLTHIOPYRIDINES FOR CONTROLLING HELICOBACTER BACTERIA | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1995-09-27 | — | — | EP | disclosed |
| WO-1994013290-A1 | USE OF ALKYLTHIOPYRIDINES FOR CONTROLLING HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1994-06-23 | — | — | WO | disclosed |
| EP-0015601-B1 | PHOTOGRAPHIC SILVER HALIDE MATERIALS COMPRISING LIGHT-ABSORBING DYES | AGFA-GEVAERT N.V. (BE) | 1983-05-11 | — | — | EP | disclosed |
| US-4288534-A | Photographic silver halide materials containing light-absorbing dyes | AGFA-GEVAERT, N.V. (BE) | 1981-09-08 | — | — | US | disclosed |
| EP-0015601-A1 | Photographic silver halide materials comprising light-absorbing dyes | AGFA-GEVAERT N.V. (BE) | 1980-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186958-A1 | GLYCOSIDASE INHIBITORS | ENGASE, GAA, GLA | GAA 2/4885RECQL 530/4885KDM4E 1588/4885 |
| US-20070213364-A1 | Alkoxyphenylpropanoic Acid Derivatives | GPR119, FFAR1, GPR55 | GAA 1246/4885RECQL 4806/4885KDM4E 2755/4885 |
| US-10005740-B2 | Neprilysin inhibitors | MME, REN, AGTR1 | GAA 161/4885RECQL 1445/4885KDM4E 2253/4885 |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | GAA 427/4885RECQL 2265/4885KDM4E 3817/4885 |
| US-20180118696-A1 | NEPRILYSIN INHIBITORS | MME, REN, AGTR1 | GAA 161/4885RECQL 1445/4885KDM4E 2253/4885 |
| US-20170144971-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | GAA 1768/4885RECQL 718/4885KDM4E 734/4885 |
| US-20170137388-A1 | NEPRILYSIN INHIBITORS | MME, REN, AGTR1 | GAA 161/4885RECQL 1445/4885KDM4E 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.